7 drugs likely to hit $1B in annual revenue in the next 5 years

Seven new drugs are expected to reach $1 billion in annual revenue in the next five years, according to a report issued Jan. 10 by analytics firm Clarivate.

Advertisement
Katie Adams

Six of the drugs are awaiting FDA approval, and one (tezepelumab) just won approval. Here is a list:

  1. Adagrasib: a drug designed to treat colorectal cancer with the KRASG12C mutation, produced by Mirati Therapeutics and Zai Lab.
  2. Donanemab: a drug designed to slow cognitive decline, produced by Eli Lilly.
  3. Faricimab: a drug designed to treat patients with diabetic macular edema or wet age-related macular degeneration, produced by Roche and Chugai Pharmaceutical.
  4. Lecanemab: a drug designed to slow cognitive decline, produced by Eisai and Biogen.
  5. Tezepelumab: an asthma drug produced by Amgen and AstraZeneca.
  6. Tirzepatide: a drug designed to address weight loss and glycemic control, produced by Eli Lilly.
  7. Vutrisiran: a drug designed to treat ATTR, produced by Alnylam Pharmaceuticals.

The high cost of poor documentation: How SSM Health, Temple and Ochsner are fighting back

Recommended Whitepaper

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.